Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD-CAA prevention (KD-CAAP) trial.

Eleftheriou D, Connon R, Tulloh R, Martin N, Kucera F, Christov G, Kahn R, Mossberg M, Nordenhäll C, Bailhache M, Palmu S, Webb C, McCrossan B, Herberg J, Moraes YC, McCormack R, Stone J, Hunter R, Walker AS, Brogan P, KD-CAAP trial investigatorsq, KD-CAAP trial investigators

Open source

DOI: 10.1016/j.eclinm.2026.104044
Published: 2026 Jul
Container: EClinicalMedicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.eclinm.2026.104044,
  title = {Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD-CAA prevention (KD-CAAP) trial.},
  author = {Eleftheriou D and Connon R and Tulloh R and Martin N and Kucera F and Christov G and Kahn R and Mossberg M and Nordenhäll C and Bailhache M and Palmu S and Webb C and McCrossan B and Herberg J and Moraes YC and McCormack R and Stone J and Hunter R and Walker AS and Brogan P and KD-CAAP trial investigatorsq and KD-CAAP trial investigators},
  year = {2026},
  journal = {EClinicalMedicine},
  doi = {10.1016/j.eclinm.2026.104044},
  url = {https://doi.org/10.1016/j.eclinm.2026.104044}
}

RIS

TY  - JOUR
TI  - Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD-CAA prevention (KD-CAAP) trial.
AU  - Eleftheriou D
AU  - Connon R
AU  - Tulloh R
AU  - Martin N
AU  - Kucera F
AU  - Christov G
AU  - Kahn R
AU  - Mossberg M
AU  - Nordenhäll C
AU  - Bailhache M
AU  - Palmu S
AU  - Webb C
AU  - McCrossan B
AU  - Herberg J
AU  - Moraes YC
AU  - McCormack R
AU  - Stone J
AU  - Hunter R
AU  - Walker AS
AU  - Brogan P
AU  - KD-CAAP trial investigatorsq
AU  - KD-CAAP trial investigators
PY  - 2026
JO  - EClinicalMedicine
DO  - 10.1016/j.eclinm.2026.104044
UR  - https://doi.org/10.1016/j.eclinm.2026.104044
ER  -

APA

D, E., R, C., R, T., N, M., F, K., G, C., R, K., M, M., C, N., M, B., S, P., C, W., B, M., J, H., YC, M., R, M., J, S., R, H., AS, W., P, B., investigatorsq, K. T., & investigators, K. T. (2026). Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD-CAA prevention (KD-CAAP) trial.. EClinicalMedicine. https://doi.org/10.1016/j.eclinm.2026.104044

Source records

pubmed · retrieved 2026-09-25T16:20:04.749Z